Investors purchased shares of Pfizer, Inc. (NYSE:PFE) on weakness during trading hours on Friday. $130.95 million flowed into the stock on the tick-up and $69.99 million flowed out of the stock on the tick-down, for a money net flow of $60.96 million into the stock. Of all equities tracked, Pfizer had the 15th highest net in-flow for the day. Pfizer traded down ($0.01) for the day and closed at $35.96

Several analysts recently weighed in on the stock. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $35.00 to $39.00 in a research note on Wednesday. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective on the stock. in a research note on Wednesday, September 13th. Jefferies Group LLC set a $37.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Monday. Finally, BMO Capital Markets reissued a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research note on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $38.04.

The firm’s 50-day moving average is $33.78 and its 200 day moving average is $33.53. The company has a market cap of $213.87 billion, a PE ratio of 26.31 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the company posted $0.64 EPS. Pfizer’s revenue was down 1.9% on a year-over-year basis. Equities research analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

In related news, insider Sally Susman sold 38,230 shares of Pfizer stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Janus Henderson Group PLC lifted its position in Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock valued at $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. lifted its position in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Renaissance Technologies LLC purchased a new position in Pfizer during the 2nd quarter valued at about $268,389,000. Canada Pension Plan Investment Board lifted its position in Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock valued at $359,871,000 after acquiring an additional 7,649,416 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its position in Pfizer by 42.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock valued at $598,519,000 after acquiring an additional 5,281,314 shares during the period. 69.00% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Traders Buy Pfizer, Inc. (PFE) on Weakness” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/22/traders-buy-pfizer-inc-pfe-on-weakness-3.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.